SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2802Incyte Corporation ( INCY) announced today that it has earned a $50 million milenigel bates-11/15/2012
2801Aw, man... "...proteasome-associated autoinflammatory syndromes such as chfred hayes-11/13/2012
2800Looks good. New trial..... <i>Compassionate Use Protocol for the Treatscaram(o)uche-11/13/2012
2799incy/lly additional P2 RA results look good (he says). Baricitinib advancing tofred hayes-11/13/2012
2798>> bullish for the INCY compound baricitinib << Yup. >> liscaram(o)uche-11/7/2012
2797The label for XELJANZ (tofacitinib) is bullish for the INCY compound baricitinibBiotech Jim-11/7/2012
2796Broad second-line label is what PFE was hoping for.DewDiligence_on_SI-11/6/2012
2795Tofacitinib approved. fda.gov <i>The FDA approved Xeljanz with a Risk Escaram(o)uche-11/6/2012
2794RA-BEAM recruiting, as of 11/2.... Friday. :-) 149 study sites. Congrats toscaram(o)uche-11/5/2012
2793Two more phase III's ready..... clinicaltrials.gov So...... RA-BEGIN, escaram(o)uche-11/2/2012
2792They still won't verify that 110 is jak1-specific. "Joint" (INCY ascaram(o)uche-11/1/2012
2791NCI (P.I. is Kevin C Conlon, M.D.)........ clinicaltrials.gov Open label, jakscaram(o)uche-10/23/2012
2790and versus methotrexate only...... clinicaltrials.govscaram(o)uche-10/22/2012
2789Looks like the primary endpoint is beating placebo (rather than Humira) on ACR20DewDiligence_on_SI-10/21/2012
2788ready to go, versus humira......... clinicaltrials.govscaram(o)uche110/21/2012
2787Mt. Sinai, PRIME Trial (P.I. is John Mascarenhas, M.D.)..... <i>Phase I/scaram(o)uche-10/17/2012
2786H. Lee Moffitt (P.I. is Javier Pinilla-Ibarz, M.D., Ph.D.)...... clinicaltrialscaram(o)uche-10/15/2012
2785And we know that patients feel better in a very short period of time. Jakafi scaram(o)uche-10/11/2012
2784If I'm reading this right, the comparable for tofacitinib at 6 months is: Pravda-10/11/2012
2783Yup, real good numbers. Certain that you saw this, from today.......... financscaram(o)uche-10/11/2012
2782Those are good numbers - ACR50 at 6 months for Enbrel is typically around 40% ifBiomaven-10/11/2012
2781Six month data is posted in the ACR abstract, don't know when it went up an scaram(o)uche-10/11/2012
2780Yes, yes, and yes. They might be able to compete, but they wouldn't be ablscaram(o)uche-9/21/2012
2779 Do you track pharmaceutical companies in the weight loss, neuropathy or anti-inhorakloraine-9/21/2012
2778rheumatology.org (hope that works!)scaram(o)uche-9/18/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News